SCHEMBL21515519

SCHEMBL21515519

C=N/C(=C\C=C(C)C)c1ccccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.47
▸ ALDH1A1 P00352 4/20 0.46
▸ CES2 O00748 1/20 0.40
▸ CES1 P23141 1/20 0.40
▸ LMNA P02545 2/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ NAPRT Q6XQN6 1/20 0.39
▸ P4HTM Q9NXG6 1/20 0.39
▸ GSK3B P49841 1/20 0.39
▸ RAB9A P51151 7/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ HTT P42858 2/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ PTBP1 P26599 1/20 0.38
▸ OPRK1 P41145 1/20 0.38
▸ TOP2A P11388 1/20 0.38
▸ NPC1 O15118 3/20 0.38
▸ AGTR1 P30556 2/20 0.38
▸ PKM P14618 2/20 0.37
▸ POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21953560 0.82 KDM4E (0.48) KDM4EALDH1A1CES2CES1LMNA
SCHEMBL20903539 0.82 KDM4E (0.42) KDM4EALDH1A1CES2CES1LMNA
SCHEMBL19480611 0.77 ALDH1A1 (0.53) KDM4EALDH1A1CES2CES1LMNA
SCHEMBL22868912 0.75 CCR1 (0.34) RAB9ATDP1MAPT
SCHEMBL18738976 0.73 KDM4E (0.47) KDM4EALDH1A1CES2CES1LMNA
SCHEMBL22071486 0.73 CES2 (0.34) KDM4EALDH1A1CES2CES1LMNA
SCHEMBL25619948 0.72 KDM4E (0.37) KDM4EALDH1A1CES2CES1LMNA
SCHEMBL14818573 0.71 ALDH1A1 (0.47) KDM4EALDH1A1CES2CES1LMNA
SCHEMBL23343244 0.70 KDM4E (0.52) KDM4EALDH1A1CES2CES1LMNA
SCHEMBL20697741 0.70 KDM4E (0.43) KDM4EALDH1A1CES2CES1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11046683-B2 Activator of TREK (TWIK RElated K+ channels) channels ONO PHARMACEUTICAL CO., LTD. (JP) 2021-06-29 — — US disclosed
US-20190322662-A1 ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS ONO PHARMACEUTICAL CO., LTD. (JP) 2019-10-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190322662-A1 ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS KCNJ11, KCNJ1, KCNJ8 KDM4E 3251/4885ALDH1A1 2897/4885CES2 2031/4885
US-11046683-B2 Activator of TREK (TWIK RElated K+ channels) channels KCNJ11, KCNJ1, KCNJ8 KDM4E 3251/4885ALDH1A1 2897/4885CES2 2031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback